Gibson Dunn Advises Dianthus Therapeutics on $719 Million Upsized Offering of Common Stock and Pre-Funded Warrants
Firm News | March 17, 2026
Gibson Dunn represented Dianthus Therapeutics, Inc. on a public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering generated aggregate gross proceeds of approximately $719 million to Dianthus.
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. The company is headquartered in New York.
Gibson Dunn regularly advises clinical-stage biotechnology companies on capital markets offerings in the life sciences sector.
The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Nicholas Linke, Jasmine Vitug, and Lauren Guzman.